Search Within

Michael Morris

Formats
  1. Meeting Abstract (273)
  2. Journal Article (266)
  3. Review (19)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (580)
  2. Genitourinary Oncology Service (580)
  3. Solid Tumor Oncology Division (580)
  4. Radiology, Department of (163)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (140)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (21)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (238)
  2. Journal of Nuclear Medicine (43)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (248)
  2. American Association for Cancer Research (43)
  3. Society of Nuclear Medicine (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (39)
  6. Elsevier Inc. (27)

More Publishers

Results (580)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer
    Journal Article

    Truong, H.; Breen, K.; Nandakumar, S.; Sjoberg, D. D.; Kemel, Y.; Mehta, N.; Lenis, A. T.; Reisz, P. A.; Carruthers, J.; Benfante, N.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Advances in prostate cancer imaging
    Book Section

    Razmaria, A. A.; Schoder, H.; Morris, M. J.
    In Stratton, K. L.; Morgans, A. K. (Eds.) Urologic Oncology: Multidisciplinary Care for Patients (2022)

    Fulltext@MSK | Save
  • Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling
    Meeting Abstract

    Zaidi, S.; Zhao, J.; Chan, J.; Martine, R.; Wadosky, K.; Gopalan, A.; Karthaus, W.; Watson, P.; True, L.; Nelson, P.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus SOC versus SOC alone in patients with metastatic HSPC
    Meeting Abstract

    Berthold, D.; Tagawa, S.; Sartor, O.; Parker, C.; Saad, F.; Sakharova, O.; de Bono, J.; Feng, F.; Fizazi, K.; Morris, M.
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • PSMAfore: A phase 3 study comparing 177Lu-PSMA-617 treatment with change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
    Meeting Abstract

    Lorch, A.; Berthold, D.; Burger, I.; Morris, M.; Sartor, O.; Chi, K.; de Bono, J.; Shore, N.; Crosby, M.; Dalal, D.; more...
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
    Meeting Abstract

    Aggarwal, R.; Heller, G.; Hillman, D.; Xiao, H.; Picus, J.; Wang, J.; Taplin, M. E.; Dorff, T.; Appleman, L. J.; Weckstein, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer
    Meeting Abstract

    Linch, M.; Liu, G.; Crabb, S. J.; Beer, T. M.; Heath, E.; Gordon, M.; de Bono, J. S.; Pashova, H. I.; Tudor, I. C.; Custodio, J. M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castrationresistant prostate cancer in the VISION trial
    Meeting Abstract

    Armstrong, A. J.; Sartor, O.; Saad, F.; Czernin, J.; Shore, N. D.; Kendi, A. T.; Beer, T. M.; Vaishampayan, N.; El-Haddad, G.; Wu, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial
    Meeting Abstract

    Morris, M. J.; de Bono, J. S.; Nagarajah, J.; Wei, X. X.; Nordquist, L. T.; Koshkin, V. S.; Vickers, A.; Mirante, O.; Ghouse, R.; Tagawa, S. T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Halabi, S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Parmar, M. K.; Hussain, M.; Tangen, C.; Thompson, I. M.; Xie, W.; Carducci, M. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save